Medtronic Plc (MDT)

In May 2025, Medtronic's stock experienced a significant drop of over 7% following its fiscal Q3 2025 earnings report. In August 2025, Medtronic reported Q1 2026 results, with adjusted EPS of $1.26, beating consensus estimates, and revenue of $8.58 billion, surpassing forecasts. In September 2025, Medtronic announced a quarterly dividend of $0.71 per share. In October 2025, analysts updated their price targets and ratings for Medtronic, and the company announced new long-term results from its SPYRAL HTN-ON MED clinical trial. Over the past 52 weeks, Medtronic shares have risen 3.1%.

Demand for Medtronic Plc's products and services is generally considered to be less seasonal compared to other sectors due to the essential nature of medical products and services. Medtronic's diversified portfolio addresses essential medical needs, contributing to a consistent demand profile. The company aims to offer a consistent cadence of earnings growth of 6-8% per annum over a reasonably long duration, supported by a strong pipeline of products.

Medtronic Plc is a global leader in healthcare technology, developing and manufacturing healthcare technologies and therapies. The company is headquartered in Galway, Ireland, with operational headquarters in Minneapolis, Minnesota, U.S. Medtronic operates within the medical equipment industry and the broader healthcare technology sector. Its product portfolio includes the Cardiovascular Portfolio, which focuses on cardiac rhythm disorders, cardiovascular disease, and heart and vascular-related disorders. The Neuroscience Portfolio focuses on neurostimulation therapies, drug delivery systems for chronic pain, and products for spine and brain conditions. The Medical Surgical Portfolio covers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products. The Diabetes Operating Unit provides solutions for diabetes management, including insulin pump systems and continuous glucose monitoring systems.

Medtronic Plc operates in over 150 countries and employs more than 95,000 people worldwide. Approximately 50% of its sales are generated internationally. The company has a strategic presence in key markets such as the United States, Western Europe, and Japan. Its manufacturing and research footprint increased by 2% to approximately 9.8 million sq ft as of April 2023. Top manufacturing locations by square footage include Connecticut, Puerto Rico, Mexico, China, Minnesota, and Ireland.

Medtronic maintains a strong brand reputation, supported by its financial performance, diverse product portfolio, and commitment to innovation and R&D. The company is dedicated to advancing health equity, inclusion, diversity & equity, and protecting the planet. However, Medtronic's reputation was impacted by a significant recall of its MiniMed 600 series insulin pumps on May 22, 2025, due to potential malfunctions.

As of October 2025, 82.06% of Medtronic Plc's stock is owned by hedge funds and other institutional investors. There are 2450 institutions that hold shares in Medtronic PLC. Notable institutional activities include Ballast Advisors LLC increasing its holdings by 73.5% in the second quarter of 2025, and Boston Partners significantly raising its stake by 122.8% in the first quarter to over 6.9 million shares. Sivik Global Healthcare LLC also increased its holdings by purchasing an additional 5,000 shares. Insider activity includes Director William R. Jellison acquiring 2,500 shares in August 2025.